RAPT Therapeutics Proposed Sale to GSK Under Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Source: Businesswire
- Investigation Launched: Former Louisiana Attorney General Charles C. Foti and Kahn Swick & Foti law firm are investigating the proposed sale of RAPT Therapeutics to GSK, aiming to assess the adequacy of the transaction process and its terms.
- Transaction Terms Overview: Under the proposed terms, RAPT shareholders will receive $58.00 in cash per share, raising questions about whether this price adequately reflects the company's value, necessitating further scrutiny.
- Legal Rights Consultation: KSF encourages shareholders who believe the transaction undervalues the company to reach out for discussions regarding their legal rights, indicating potential disputes surrounding the deal.
- Urgency Reminder: As the transaction is structured as a tender offer, KSF emphasizes the importance of prompt action by shareholders to ensure their rights are protected.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
